drugset / Trial / NCT02103257
Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung Adenocarcinoma
RandomizedParallel-groupOpen-labelTreatment
Summary
This randomised, controlled, multicentre trial is designed to assess the efficacy and safety of sequential icotinib plus chemotherapy versus single icotinib as first-line treatment in stage IIIB/IV lung adenocarcinoma patients with EGFR mutation.
Timeline
- Start
- 2014-03
- Primary completion
- 2016-03
- Completion
- 2017-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cisplatin | Other / unclassified | 75 mg/m2 | — |
| Comparator | Icotinib | Small molecule | 125 mg | Oral |
| Subject | Pemetrexed | Small molecule | 500 mg/m2 | Intravenous |